Skip to Content

EHA l European Hematology Association’s Annual Congress

EHA 2024

Promising Avenues for the Development of Personalized Treatment for FVII Deficiency

July 2024 / Maria Eugenia Chollet

EHA24

Vaccinating Against Mutated RAS in Multiple Myeloma

July 2024 / Hanne Norseth

EHA24 Myeloma

ASH | Congress

We cover the most interesting news from the ASH Congress through abstracts, online articles and MEDtalk videos from experts and specialists worldwide.

Go to page

Back to top

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Necessary

Always Enabled

Non Necessary

Analytics

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.

Cookie	Duration	Description
_ga	2 years	This cookie is installed by Google Analytics. The cookie is used to calculate visitor, session, camapign data and keep track of site usage for the site's analytics report. The cookies store information anonymously and assigns a randoly generated number to identify unique visitors.
_gid	1 day	This cookie is installed by Google Analytics. The cookie is used to store information of how visitors use a website and helps in creating an analytics report of how the wbsite is doing. The data collected including the number visitors, the source where they have come from, and the pages viisted in an anonymous form.

Preferences

Preference cookies are used to store user preferences to provide content that is customized and convenient for the users, like the language of the website or the location of the visitor.

Cookie	Duration	Description
_gat_UA-43794127-5	1 minute	This is a pattern type cookie set by Google Analytics, where the pattern element on the name contains the unique identity number of the account or website it relates to. It appears to be a variation of the _gat cookie which is used to limit the amount of data recorded by Google on high traffic volume websites.

EHA l European Hematology Association’s Annual Congress

EHA 2024

Promising Avenues for the Development of Personalized Treatment for FVII Deficiency

Vaccinating Against Mutated RAS in Multiple Myeloma

Epcoritamab with Rituximab and Lenalidomide (R2) for Patients with High-Risk Follicular Lymphoma

Gilteritinib for Patients with Newly Diagnosed AML

MURANO Study Supports the Use of Fixed-Duration VenR in R/R CLL

Daratumumab Combination Shows Positive Responses in Pretreated R/R Multiple Myeloma

News from EHA23 – A Promising Treatment Option for Follicular Lymphoma

What is New from EHA23 Regarding Treatment Strategies in First-Line CLL?

Risk of Dementia in Older Patients Treated with Chemotherapy for Lymphoma

Belamaf and Dexamethasone – Safe, Effective Multiple Myeloma Treatment

New Research from EHA23 Points to Similar Effectiveness of Acalabrutinib and Zanubrutinib in R/R CLL Treatment

UK Trial Gives Voice to CLL Patients’ Experiences with Targeted Therapies

Impact of First-Year Dose Modifications of Acalabrutinib in Patients with CLL

Functional Characterization for Germline Variants in Patients with MDS and AML

LBA: Oral Vitamin C Supplementation for Patients with Early-Stage Myeloid Malignancies and Precursor Conditions Might Improve OS

Elderly Patients with Mantle Cell Lymphoma Need to be More Intensively Treated

New Insights into MM Heterogeneity Among Different Age Groups

ASH | Congress

Name & work area

EHA l European Hematology Association’s Annual Congress

EHA 2024

EHA 2023

Epcoritamab with Rituximab and Lenalidomide (R2) for Patients with High-Risk Follicular Lymphoma

Gilteritinib for Patients with Newly Diagnosed AML

MURANO Study Supports the Use of Fixed-Duration VenR in R/R CLL

Daratumumab Combination Shows Positive Responses in Pretreated R/R Multiple Myeloma

News from EHA23 – A Promising Treatment Option for Follicular Lymphoma

What is New from EHA23 Regarding Treatment Strategies in First-Line CLL?

Risk of Dementia in Older Patients Treated with Chemotherapy for Lymphoma

Belamaf and Dexamethasone – Safe, Effective Multiple Myeloma Treatment

New Research from EHA23 Points to Similar Effectiveness of Acalabrutinib and Zanubrutinib in R/R CLL Treatment

UK Trial Gives Voice to CLL Patients’ Experiences with Targeted Therapies

Impact of First-Year Dose Modifications of Acalabrutinib in Patients with CLL

Functional Characterization for Germline Variants in Patients with MDS and AML

LBA: Oral Vitamin C Supplementation for Patients with Early-Stage Myeloid Malignancies and Precursor Conditions Might Improve OS

Elderly Patients with Mantle Cell Lymphoma Need to be More Intensively Treated

New Insights into MM Heterogeneity Among Different Age Groups

ASH | Congress

More from EHA